NCT06773091View on ClinicalTrials.gov

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

NK042

NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors and enriched with NKR+ NK cells.

DRUG

Fludarabine (FLU)

Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.

DRUG

Cyclophosphamide (CTX)

Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Shanghai NK Cell Technology Co., LTD

INDUSTRY

NCT06773091 - A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter